lencana Anda Rentang 52M $123–$186 36% of range Peringkat Analis BUY 36 analysts Target Harga $208 +43% upside P/E 21.3 ROE 22.1% Margin Laba Bersih 20.9%

NBIX Cuplikan Saham Harga, kapitalisasi pasar, P/E, EPS, ROE, utang/ekuitas, kisaran 52 minggu

03
Harga $145.51
Kapitalisasi Pasar (MRQ) $14.78B
P/E (TTM) 21.3
EPS (TTM) $6.83
Pendapatan (TTM) $3.37B
ROE (TTM) 22.1%
Rentang 52M $123–$186

NBIX Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda

04
rentang
batang

Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.

Tentang Neurocrine Biosciences, Inc. - Common Stock Tinjauan perusahaan dari Wikipedia

05 · wikidata

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

History

Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.

In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.

In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.

In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.

In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.

Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.

On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.

In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.

In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.

In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.

In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.

In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.

Product pipeline

Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids

Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease

NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist

NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.

Sumber: Wikipedia (English), CC BY-SA 4.0 · Lihat di Wikipedia ↗

Wikidata ↗

sektorHealthcare industriBiotechnology karyawan2.500 negaraUS

Kinerja 10 Tahun Tren Pendapatan, laba bersih, margin, dan EPS

06
Pendapatan$2.86B
2016-12-31 → 2025-12-31
EPS$4.67
2016-12-31 → 2025-12-31
Arus Kas Bebas$749M
2016-12-31 → 2025-12-31
Margin bersih20.9%
2016-12-31 → 2025-12-31
Valuasi & Rasio 07–12

Valuasi Rasio P/E, P/S, P/B, EV/EBITDA — apakah sahamnya mahal atau murah?

Metrik Tren 5 Tahun NBIX rata-rata 5T Median Rekan Kesimpulan
P/E (TTM) 21.3rata-rata 5T ≈58.9 ≈58.9 19.4 Terlalu mahal
P/S (TTM) 4.4rata-rata 5T ≈6.5 ≈6.5 7.3 Kurang nilai
P/B (MRQ) 4.0rata-rata 5T ≈5.6 ≈5.6 14.5 Kurang nilai
Harga / FCF (TTM) 17.0rata-rata 5T ≈29.9 ≈29.9 · ·
Harga / Arus Kas (TTM) 16.5rata-rata 5T ≈28.0 ≈28.0 13.6 Terlalu mahal
Harga / Nilai Buku Berwujud (MRQ) 10.1rata-rata 5T ≈5.7 ≈5.7 · ·
PEG Ratio (Rasio PEG) ≈9.1 · · ·

Median rekan dihitung berdasarkan basis standar per metrik dan mungkin tidak selalu cocok dengan basis TTM/MRQ yang ditampilkan untuk saham ini.

nilai · ≈ rata-rata 5T · median industri · penilaian relatif terhadap median

Riwayat Pendapatan EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya

14
Kejutan Rata-rata 11.3%
Laporan Berikutnya Okt 26, 2026
PeriodeLaporanEPS AktualEPS EstimasiKejutan
30 Juni 2026 Jul 28, 2026 $1.39 $1.37 1.5%
31 Maret 2026 $1.91 $1.20 59.5%
31 Des. 2025 $1.91 $1.20 59.5%
30 Sep. 2025 $2.04 $1.62 26.1%
30 Juni 2025 $1.06 $0.99 7.0%
31 Maret 2025 $0.08 $0.56 -85.6%

Fundamental Lengkap Semua metrik per tahun — laporan laba rugi, neraca, arus kas

15
Laporan Laba Rugi 17
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue $2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788M$451M$162M$15M$20M$0
Cost of Revenue $52M$34M$40M$23M$14M$10M·$5M$1M$0$0·
R&D Expense ·······$161M$122M$94M$81M$46M
SG&A Expense $1.16B$1.01B$888M$753M$583M$433M$354M$249M$170M$68M$32M$18M
Operating Expenses $2.24B$1.78B$1.64B$1.24B$1.03B$883M$716M$414M$293M$162M$114M$64M
Operating Income $619M$570M$251M$249M$102M$163M$72M$37M$-131M$-147M$-94M$-64M
Interest Expense ··$5M$7M$26M$33M$32M$30M$20M$0$0·
Interest Income ·········$3M$2M$629.0K
Other Non-op $86M$-84M$81M$-35M$-1M$-56M$-26M$-15M$-11M$6M$20.0K$18.0K
Pretax Income $705M$486M$332M$214M$101M$107M$46M$22M$-143M$-141M··
Income Tax $227M$145M$82M$59M$12M$-301M$10M$700.0K$0$0$0$0
Net Income $479M$341M$250M$154M$90M$407M$37M$21M$-143M$-141M$-89M$-61M
EPS (Basic) $4.81$3.40$2.56$1.61$0.95$4.38$0.40$0.23$-1.62$-1.63$-1.05$-0.81
EPS (Diluted) $4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63$-1.05$-0.81
Shares (Basic) 99,500,000100,400,00097,700,00095,800,00094,600,00093,100,00091,600,00090,200,00088,089,00086,713,00084,496,00074,577,000
Shares (Diluted) 102,500,000103,700,000101,000,00098,900,00097,900,00097,800,00095,700,00095,400,00088,089,00086,713,00084,496,00074,577,000
EBITDA $619M$570M$251M$249M$102M$163M$72M$37M$-131M$-147M·$-64M
Neraca 28
Metrik Tren 202520242023202220212020201920182017201620152014
Cash & Equivalents $713M$233M$251M$263M$341M$187M$112M$142M$255M$83M$74M$31M
Short-term Investments ····$370M$614M$558M$509M$261M$224M$305M$163M
Receivables $687M$479M$439M$350M$186M$157M$127M$57M$31M$0··
Inventory $69M$57M$38M$35M$30M$28M$17M$11M$1M$0··
Prepaid Expense $171M$48M··········
Other Current Assets $116M$64M$98M$79M$46M$30M$17M$19M$7M$3M$5M$4M
Current Assets $2.52B$1.72B$1.61B$1.45B$973M$1.02B$831M$738M$555M$310M$384M$198M
PP&E (Net) $90M$83M$71M$59M$59M$45M$42M$34M$11M$6M$3M$3M
PP&E (Gross) $208M$189M$154M$125M$110M$86M$76M$62M$38M$32M$30M$31M
Accum. Depreciation $118M$106M$83M$66M$52M$42M$34M$28M$28M$26M$27M$29M
Goodwill $6M$6M$6M$5M$0·······
Intangibles $5M$36M$36M$37M$0·······
Other Non-current Assets $49M$52M$50M$25M$4M$6M$0·····
Total Assets $4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993M$818M$365M$475M$243M
Accounts Payable $674M$462M$449M$348M$226M$169M$141M$86M$6M$5M$3M$246.0K
Accrued Liabilities ·········$21M$19M$12M
Current Liabilities $743M$508M$655M$538M$246M$186M$565M$88M$54M$30M$26M$16M
Capital Leases $415M$455M$258M$94M$105M$94M$87M$0····
Deferred Tax $0···········
Other Non-current Liabilities $220M$166M$106M$30M$12M$10M$17M$36M$0$113.0K$221.0K$260.0K
Total Liabilities $1.38B$1.13B$1.02B$661M$698M$608M$669M$512M$445M$50M$50M$34M
Common Stock $100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$91.0K$89.0K$87.0K$86.0K$76.0K
Paid-in Capital ···········$1.04B
Retained Earnings $448M$29M$-157M$-407M$-636M$-725M$-1.13B$-1.18B$-1.20B$-1.06B$-915M$-826M
AOCI $13M$6M$7M$-8M$-2M$2M$1M$-2M$-2M$-318.0K$-977.0K$-277.0K
Stockholders' Equity $3.25B$2.59B$2.23B$1.71B$1.37B$1.13B$637M$481M$372M$315M$424M$209M
Liabilities + Equity $4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993M$818M$365M$475M$243M
Shares Outstanding 100,100,00099,400,00098,700,00096,500,00094,900,00093,500,00092,300,00090,797,00088,793,90386,883,30086,262,59476,465,942
Arus Kas 15
Metrik Tren 202520242023202220212020201920182017201620152014
D&A ·······$4M$2M$1M$1M$827.0K
Stock-based Comp $218M$196M$194M$173M$134M$100M$75M$58M$43M$28M$28M$10M
Deferred Tax $164M$-123M$-61M$22M$6M$-311M$0$0····
Amort. of Intangibles $4M$4M$4M$500.0K$0$0······
Operating Cash Flow $783M$595M$390M$339M$256M$228M$147M$101M$-94M$-106M$-38M$-47M
CapEx $34M$38M$28M$16M$23M$11M$15M$25M$7M$4M$2M$2M
Investing Cash Flow $-264M$-127M$-467M$-177M$-130M$4M$-211M$-243M$-251M$113M··
Stock Issued $129M$122M$65M$45M$28M$29M$32M$30M$14M$2M$277M$139M
Stock Repurchased $168M$300M$0$0········
Net Stock Activity $-38M$-178M$65M$45M$28M$29M$27M$30M$14M$2M·$139M
Financing Cash Flow $-38M$-487M$65M$-234M$27M$-158M$32M$30M$517M$2M··
Net Change in Cash $480M$-18M$-12M$-73M$154M$75M$-32M$-112M$171M$9M$43M$-14M
Taxes Paid $81M···········
Free Cash Flow $749M$557M$362M$323M$233M$218M$137M$77M$-101M$-110M·$-49M
Levered FCF ··$358M$318M$210M$92M$112M$47M····
Profitabilitas 7
Metrik Tren 202520242023202220212020201920182017201620152014
Operating Margin 21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%··
Net Margin 16.7%14.5%13.2%10.4%7.9%38.9%4.7%4.7%-88.2%-940.6%··
Pretax Margin 24.7%20.6%17.6%14.4%8.9%10.2%5.9%4.8%····
EBITDA Margin 21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%··
ROA 11.5%9.8%8.9%7.0%4.7%26.8%3.2%2.3%-24.1%-33.6%·-30.4%
ROE 16.1%12.9%11.8%9.5%6.6%42.2%6.1%4.5%-41.5%-38.2%·-36.8%
ROIC 12.9%15.5%8.5%10.5%6.6%55.2%9.0%7.4%····
Likuiditas & Solvabilitas 3
Metrik Tren 202520242023202220212020201920182017201620152014
Current Ratio 3.43.42.52.74.05.41.58.410.210.2·12.7
Quick Ratio 1.91.41.11.13.65.11.42.210.110.1·12.4
Interest Coverage ··54.535.14.05.02.31.2-6.7···
Efisiensi 3
Metrik Tren 202520242023202220212020201920182017201620152014
Asset Turnover 0.70.70.70.70.60.70.70.50.30.0·0.0
Inventory Turnover 0.80.71.10.7···0.8····
Receivables Turnover 4.95.14.85.66.67.48.610.310.4···
Per Saham 5
Metrik Tren 202520242023202220212020201920182017201620152014
Book Value / Share $32.50$26.05$22.61$17.70$14.48$12.04$6.90$5.29$4.19$3.62·$2.73
Revenue / Share $27.91$22.71$18.68$15.05$11.58$10.69$8.23$4.73$1.83$0.17·$0.00
Cash Flow / Share $7.64$5.74$3.86$3.43$2.62$2.34$1.59$1.06$-1.07$-1.22·$-0.63
Cash / Share $7.12$2.34$2.54$2.72$3.59$2.00$1.22$1.56$2.87$0.96·$0.41
EPS (TTM) $4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63$-1.05$-0.81
Tingkat Pertumbuhan 9
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue YoY 21.4%24.8%26.8%31.3%8.4%·······
Revenue CAGR 3Y 24.3%27.6%21.7%·········
Revenue CAGR 5Y 22.3%···········
EPS YoY 41.9%33.2%58.3%69.6%-77.9%·······
EPS CAGR 3Y 44.1%52.9%-16.0%·········
EPS CAGR 5Y 2.3%···········
Net Income YoY 40.2%36.7%61.6%72.4%-78.0%·······
Net Income CAGR 3Y 45.8%56.2%-15.0%·········
Net Income CAGR 5Y 3.3%···········
Valuasi (TTM) 10
Metrik Tren 202520242023202220212020201920182017201620152014
Revenue TTM $2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788M$451M$162M$15M$20M$0
Net Income TTM $479M$341M$250M$154M$90M$407M$37M$21M$-143M$-141M$-89M$-61M
Market Cap $14.20B$13.57B$13.00B$11.53B$8.08B$8.96B$9.92B$6.48B$6.89B$3.36B·$1.71B
P/E 30.441.553.376.692.623.0275.6324.6-47.9-23.7-53.9-27.6
P/S 5.05.86.97.77.18.612.614.442.6224.2··
P/B 4.45.25.86.75.98.015.613.518.510.7·8.2
P / Tangible Book 4.45.35.96.95.98.0······
P / Cash Flow 18.122.833.434.031.539.265.264.0-73.0-31.7·-36.2
P / FCF 19.024.436.035.734.741.272.284.7-68.0-30.5·-35.0
Earnings Yield 3.3%2.4%1.9%1.3%1.1%4.3%0.36%0.31%-2.1%-4.2%-1.9%-3.6%

Periode terbaru di sebelah kiri · nilai null ditampilkan sebagai ·

Laporan Keuangan Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir

16
Metrik 2025-12-312024-12-312023-12-312022-12-312021-12-31
Pendapatan $2.86B $2.36B $1.89B $1.49B $1.13B
Margin Operasi % 21.6% 24.2% 13.3% 16.7% 9.0%
Laba Bersih $479M $341M $250M $154M $90M
EPS Dilusian $4.67 $3.29 $2.47 $1.56 $0.92

Pemilik institusional (13F) 825 pengaju · $18.1B total · Per tanggal 30 Sep. 2026

17

Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.

Pemegang 825
Nilai yang dipegang $18.1B
Posisi baru 148
Posisi yang keluar 62
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru Posisi yang keluar Meningkat Menurun Perubahan bersih saham
148 (+50 vs Kuartal sebelumnya) 62 (-36 vs Kuartal sebelumnya) 317 (+16 vs Kuartal sebelumnya) 226 (+12 vs Kuartal sebelumnya) +587K

Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.

Institusi Nilai Saham % dari 13F yang dilacak Tipe
BlackRock, Inc. $2.310.885.707 13.711.607 12,75% Saham
VANGUARD GROUP INC $1.375.793.692 9.700.301 7,59% Saham
JPMORGAN CHASE & CO $1.088.569.109 6.398.674 6,01% Saham
Dodge & Cox $941.218.594 5.584.707 5,20% Saham
VANGUARD PORTFOLIO MANAGEMENT LLC $838.307.078 4.974.083 4,63% Saham
VANGUARD CAPITAL MANAGEMENT LLC $766.048.708 4.545.339 4,23% Saham
STATE STREET CORP $739.126.759 4.385.598 4,08% Saham
AQR CAPITAL MANAGEMENT LLC $643.472.716 3.818.037 3,55% Saham
RENAISSANCE TECHNOLOGIES LLC $393.680.402 2.335.897 2,17% Saham
GEODE CAPITAL MANAGEMENT, LLC $359.607.676 2.138.777 1,98% Saham
TWO SIGMA INVESTMENTS, LP $349.922.479 2.076.260 1,93% Saham
Vestal Point Capital, LP $316.845.800 1.880.000 1,75% Saham
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $251.858.951 1.494.259 1,39% Saham
MORGAN STANLEY $222.231.858 1.318.607 1,23% Saham
RTW INVESTMENTS, LP $213.689.740 1.267.925 1,18% Saham
NORTHERN TRUST CORP $212.306.405 1.259.717 1,17% Saham
Invesco Ltd. $181.565.621 1.077.317 1,00% Saham
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $164.200.136 974.279 0,91% Saham
NORGES BANK $164.132.866 973.880 0,91% Saham
FIRST TRUST ADVISORS LP $155.578.851 923.125 0,86% Saham
DIMENSIONAL FUND ADVISORS LP $123.525.529 732.877 0,68% Saham
JACOBS LEVY EQUITY MANAGEMENT, INC $122.375.286 726.112 0,68% Saham
TWO SIGMA ADVISERS, LP $119.504.823 842.592 0,66% Saham
Bank of New York Mellon Corp $117.826.993 699.125 0,65% Saham
Swedbank AB $109.730.107 651.082 0,61% Saham
VANGUARD FIDUCIARY TRUST CO $109.170.737 647.763 0,60% Saham
IEQ CAPITAL, LLC $107.913.614 640.304 0,60% Saham
GOLDMAN SACHS GROUP INC $106.495.877 631.892 0,59% Saham
BANK OF AMERICA CORP /DE/ $104.382.489 619.352 0,58% Saham
VICTORY CAPITAL MANAGEMENT INC $104.238.729 618.499 0,58% Saham
Man Group plc $101.292.738 601.019 0,56% Saham
ROYAL BANK OF CANADA $98.337.000 583.476 0,54% Saham
RAYMOND JAMES FINANCIAL INC $97.778.953 580.170 0,54% Saham
FRANKLIN RESOURCES INC $93.211.316 553.068 0,51% Saham
UBS Group AG $92.009.492 545.937 0,51% Saham
Caisse de depot et placement du Quebec $91.002.327 539.961 0,50% Saham
ARMISTICE CAPITAL, LLC $90.307.457 535.838 0,50% Saham
AMERIPRISE FINANCIAL INC $84.660.571 502.267 0,47% Saham
PRIMECAP MANAGEMENT CO/CA/ $82.807.988 491.340 0,46% Saham
Hood River Capital Management LLC $79.082.184 469.233 0,44% Saham
Nuveen, LLC $77.408.341 459.301 0,43% Saham
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $75.318.261 571.719 0,42% Saham
Pictet Asset Management Holding SA $72.751.030 430.635 0,40% Saham
Rockefeller Capital Management L.P. $62.955.982 373.548 0,35% Saham
Fiera Capital Corp $62.895.914 373.192 0,35% Saham
Gotham Asset Management, LLC $62.622.213 371.568 0,35% Saham
JANUS HENDERSON GROUP PLC $61.515.240 466.977 0,34% Saham
ALLIANCEBERNSTEIN L.P. $60.767.710 461.270 0,34% Saham
Vinva Investment Management Ltd $58.838.530 346.109 0,32% Saham
AustralianSuper Pty Ltd $58.817.535 348.993 0,32% Saham

Tampilkan semua 825 pemilik institusional →

Aktivis & pemilik 5%+ 1 saham

18

Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.

Pengaju Diajukan Kepemilikan Status Tujuan Pengajuan
Neurocrine Biosciences, Inc. ×3 pengajuan 24 Feb. 2023 · Pengajuan awal · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Orang dalam perusahaan 41 orang dalam · 22 pejabat · 15 direktur

19
Orang Dalam Peran Aktivitas terakhir Saham dimiliki Beli 12m Jual 12m Bersih 12m
Kyle Gano Chief Executive Officer 11 Sep. 2026 F 154.728 0 3 $-4.872.890
Matt Abernethy Chief Financial Officer 14 Sep. 2026 S 42.808 0 1 $-363.289
Timothy Coughlin Chief Financial Officer 6 Feb. 2017 S 137.961 0 0 $0
David-Alexandre C Gros President & COO 6 Feb. 2017 A · 0 0 $0
David W. Boyer Chief Corp. Affairs Officer 14 Sep. 2026 S 8.722 0 2 $-739.070
Ingrid Delaet Chief Regulatory Officer 11 Sep. 2026 F 18.289 0 5 $-3.747.962
Jude Onyia Chief Scientific Officer 11 Sep. 2026 F 22.647 0 2 $-3.473.580
Sanjay Chandru Keswani Chief Medical Officer 11 Sep. 2026 F 3.281 0 0 $0
Julie Cooke Chief Human Resources Officer 11 Sep. 2026 F 24.025 0 5 $-5.770.377
Eric Benevich Chief Commercial Officer 11 Sep. 2026 F 67.297 0 2 $-1.238.918
Darin Lippoldt Chief Legal Officer 11 Sep. 2026 F 56.793 0 5 $-4.196.071
Eiry Roberts Chief Medical Officer 13 Feb. 2025 M 35.640 0 0 $0
Malcolm Lloyd-Smith Chief Integration Officer 8 Feb. 2023 S 42.337 0 0 $0
Dimitri E. Grigoriadis Chief Research Officer 31 Jan. 2022 A 82.273 0 0 $0
Haig P. Bozigian Chief Development Officer 8 Feb. 2021 A 157.651 0 0 $0
Christopher Flint Obrien Former Chief Medical Officer 5 Feb. 2018 A 55.946 0 0 $0
VALEUR JENSEN MARGARET E EVP and General Counsel 31 Agu 2011 A 118.256 0 0 $0
Richard J Ranieri Sr. VP, Human Resources 27 Feb. 2008 A 9.667 0 0 $0
Wendall Wierenga EVP, Research & Development 19 Jan. 2006 A 5.023 0 0 $0
Henry Pan Executive VP and CMO 3 Juni 2005 A 11.216 0 0 $0
Robert J Little SVP, Commercial Operations 18 Feb. 2005 A · 0 0 $0
SAUNDERS JOHN Vice President Research (Chem) 18 Des. 2003 S 7.966 0 0 $0
Kevin Charles Gorman Direktur 11 Sep. 2026 F 517.797 0 1 $-37.824.431
SHERWIN STEPHEN A Direktur 2 Sep. 2026 G 14.860 0 5 $-4.132.990
Leslie V Norwalk Direktur 29 Juli 2026 M 2.430 0 5 $-1.973.882
Johanna Mercier Direktur 27 Mei 2026 A 6.853 0 0 $0
William H Rastetter Direktur 27 Mei 2026 A 43.678 0 1 $-2.732.760
Christine A Poon Direktur 27 Mei 2026 A 4.753 0 0 $0
POPS RICHARD F Direktur 27 Mei 2026 A 37.798 0 1 $-2.364.750
LYONS GARY A Direktur 27 Mei 2026 A 122.141 0 1 $-2.289.150
MORROW GEORGE J Direktur 27 Mei 2026 A 10.386 0 1 $-2.150.550
Alfred Sandrock Direktur 22 Mei 2019 A · 0 0 $0
Corinne H Nevinny Direktur 24 Mei 2018 A 43.283 0 0 $0
Thomas W Mitchell Direktur 28 Mei 2015 A 1.000 0 0 $0
VALE WYLIE W Direktur 25 Mei 2011 A 231.372 0 0 $0
Adrian Adams Direktur 30 Juni 2006 A · 0 0 $0
Shalini Sharp · 27 Mei 2026 A 4.088 0 0 $0
MOLLICA JOSEPH A · 22 Mei 2017 A 56.042 0 0 $0
HAWRAN PAUL W · 18 Sep. 2006 J 132.000 0 0 $0
Lawrence Steinman · 2 Maret 2005 S 15.500 0 0 $0
CONLON PAUL J · 16 Des. 2003 S 57.335 0 0 $0

Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka

Kepemilikan ETF Dimiliki oleh 104 ETF

20

Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.

Dana Bobot Unit Per tanggal Sumber
IBRN · iShares Trust 3,75% 1.793 SH 11 Sep. 2026 Harian
PBE · Invesco Exchange-Traded Fund Trust 2,64% 76.686 SH 5 Okt. 2026 Harian
MCOW · Pacer Funds Trust 2,57% 164 NS 31 Juli 2026 N-PORT
BUL · Pacer Funds Trust 2,15% 16.896 NS 31 Juli 2026 N-PORT
CVSM · Elevation Series Trust 2,04% 11.525 NS 31 Juli 2026 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1,95% 22.570 SH 5 Okt. 2026 Harian
JMID · Janus Detroit Street Trust 1,93% 2.742 NS 31 Juli 2026 N-PORT
FGSI · First Trust Exchange-Traded Fund IV 1,90% 236 NS 31 Juli 2026 N-PORT
ABOT · Abacus FCF ETF Trust 1,90% 460 NS 31 Juli 2026 N-PORT
XMHQ · Invesco Exchange-Traded Fund Trust 1,76% 667.222 SH 5 Okt. 2026 Harian
FXH · First Trust Exchange-Traded AlphaDE… 1,67% 105.135 NS 31 Juli 2026 N-PORT
GRPM · Invesco Exchange-Traded Fund Trust 1,64% 56.862 SH 5 Okt. 2026 Harian
BBP · ETFis Series Trust I 1,44% 8.494 NS 31 Juli 2026 N-PORT
CSMD · Professionally Managed Portfolios 1,18% 32.094 NS 31 Juli 2026 N-PORT
IBB · iShares Trust 1,14% 755.021 SH 11 Sep. 2026 Harian
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… 1,11% 7.516 NS 31 Juli 2026 N-PORT
RFG · Invesco Exchange-Traded Fund Trust 1,05% 24.859 SH 5 Okt. 2026 Harian
JSMD · Janus Detroit Street Trust 1,05% 66.455 NS 31 Juli 2026 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 0,98% 7.259 SH 5 Okt. 2026 Harian
IVOG · VANGUARD ADMIRAL FUNDS 0,89% 99.214 SH 19 Agu 2026 Harian
COWG · Pacer Funds Trust 0,78% 103.520 NS 31 Juli 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0,73% 399 NS 31 Juli 2026 N-PORT
QQQJ · Invesco Exchange-Traded Fund Trust … 0,72% 59.939 SH 5 Okt. 2026 Harian
LSEQ · Harbor ETF Trust 0,72% 661 NS 31 Juli 2026 N-PORT
LABU · Direxion Shares ETF Trust 0,71% 20.978 NS 31 Juli 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0,63% 12.528 NS 31 Juli 2026 N-PORT
FNY · First Trust Exchange-Traded AlphaDE… 0,63% 21.784 NS 31 Juli 2026 N-PORT
QLV · FlexShares Trust 0,56% 5.460 NS 31 Juli 2026 N-PORT
ISCG · iShares Trust 0,52% 31.868 SH 11 Sep. 2026 Harian
PTMC · Pacer Funds Trust 0,47% 11.072 NS 31 Juli 2026 N-PORT
USMV · iShares Trust 0,46% 697.795 SH 11 Sep. 2026 Harian
VBK · VANGUARD INDEX FUNDS 0,46% 1.331.820 SH 19 Agu 2026 Harian
IVOO · VANGUARD ADMIRAL FUNDS 0,46% 162.408 SH 19 Agu 2026 Harian
QVMM · Invesco Exchange-Traded Fund Trust … 0,46% 13.274 SH 5 Okt. 2026 Harian
SMDX · Tidal Trust III 0,43% 3.374 NS 31 Juli 2026 N-PORT
BKMC · BNY Mellon ETF Trust 0,42% 16.429 NS 31 Juli 2026 N-PORT
IWP · iShares Trust 0,39% 480.949 SH 11 Sep. 2026 Harian
SDG · iShares Trust 0,38% 4.071 SH 11 Sep. 2026 Harian
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0,36% 44.021 NS 31 Juli 2026 N-PORT
MIDU · Direxion Shares ETF Trust 0,36% 1.476 NS 31 Juli 2026 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0,31% 46.187 NS 31 Juli 2026 N-PORT
FNX · First Trust Exchange-Traded AlphaDE… 0,30% 24.447 NS 31 Juli 2026 N-PORT
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0,29% 8.053 NS 31 Juli 2026 N-PORT
COWZ · Pacer Funds Trust 0,25% 283.150 NS 31 Juli 2026 N-PORT
IYH · iShares Trust 0,25% 57.843 SH 11 Sep. 2026 Harian
VHT · VANGUARD WORLD FUND 0,24% 286.599 SH 19 Agu 2026 Harian
FHLC · FIDELITY COVINGTON TRUST 0,23% 45.259 NS 31 Juli 2026 N-PORT
SMMD · iShares Trust 0,21% 52.744 SH 11 Sep. 2026 Harian
EUSA · iShares, Inc. 0,20% 25.089 SH 11 Sep. 2026 Harian
VB · VANGUARD INDEX FUNDS 0,20% 2.306.077 SH 19 Agu 2026 Harian
PWS · Pacer Funds Trust 0,20% 287 NS 31 Juli 2026 N-PORT
SIZE · iShares Trust 0,20% 5.417 SH 11 Sep. 2026 Harian
VXF · VANGUARD INDEX FUNDS 0,19% 1.153.763 SH 19 Agu 2026 Harian
FAD · First Trust Exchange-Traded AlphaDE… 0,19% 6.541 NS 31 Juli 2026 N-PORT
ACWV · iShares, Inc. 0,18% 37.854 SH 11 Sep. 2026 Harian
RWK · Invesco Exchange-Traded Fund Trust … 0,13% 11.381 SH 5 Okt. 2026 Harian
IWR · iShares Trust 0,11% 405.396 SH 11 Sep. 2026 Harian
FHEQ · Fidelity Greenwood Street Trust 0,11% 6.157 NS 31 Juli 2026 N-PORT
ESUM · Strategy Shares 0,10% 1.133 NS 31 Juli 2026 N-PORT
HEQQ · J.P. Morgan Exchange-Traded Fund Tr… 0,10% 177 NS 31 Juli 2026 N-PORT
LRND · New York Life Investments ETF Trust 0,10% 2.270 NS 31 Juli 2026 N-PORT
HELO · J.P. Morgan Exchange-Traded Fund Tr… 0,09% 23.838 NS 31 Juli 2026 N-PORT
EQAL · Invesco Exchange-Traded Fund Trust … 0,09% 4.828 SH 5 Okt. 2026 Harian
DFUV · Dimensional ETF Trust 0,08% 70.759 NS 31 Juli 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0,07% 23.598 SH 5 Okt. 2026 Harian
DYNF · BlackRock ETF Trust 0,07% 177.312 SH 11 Sep. 2026 Harian
USXF · iShares Trust 0,06% 5.665 SH 11 Sep. 2026 Harian
ESMV · iShares Trust 0,05% 26 SH 11 Sep. 2026 Harian
GARP · iShares Trust 0,05% 9.869 SH 11 Sep. 2026 Harian
DFAC · Dimensional ETF Trust 0,05% 141.631 NS 31 Juli 2026 N-PORT
DXUV · Dimensional ETF Trust 0,05% 1.484 NS 31 Juli 2026 N-PORT
DCOR · Dimensional ETF Trust 0,04% 8.569 NS 31 Juli 2026 N-PORT
IUSG · iShares Trust 0,04% 89.338 SH 11 Sep. 2026 Harian
IWF · iShares Trust 0,04% 320.069 SH 11 Sep. 2026 Harian
VONG · VANGUARD SCOTTSDALE FUNDS 0,04% 134.662 SH 19 Agu 2026 Harian
ESGV · VANGUARD WORLD FUND 0,03% 22.375 SH 19 Agu 2026 Harian
TILT · FlexShares Trust 0,03% 3.888 NS 31 Juli 2026 N-PORT
DFAU · Dimensional ETF Trust 0,03% 20.775 NS 31 Juli 2026 N-PORT
RECS · Columbia ETF Trust I 0,02% 8.549 NS 31 Juli 2026 N-PORT
DFUS · Dimensional ETF Trust 0,02% 28.885 NS 31 Juli 2026 N-PORT
IYY · iShares Trust 0,02% 4.355 SH 11 Sep. 2026 Harian
IWB · iShares Trust 0,02% 68.459 SH 11 Sep. 2026 Harian
ITOT · iShares Trust 0,02% 131.068 SH 11 Sep. 2026 Harian
IWS · iShares Trust 0,02% 20.508 SH 11 Sep. 2026 Harian
IWV · iShares Trust 0,02% 27.012 SH 11 Sep. 2026 Harian
PBUS · Invesco Exchange-Traded Fund Trust … 0,02% 15.277 SH 5 Okt. 2026 Harian
VTI · VANGUARD INDEX FUNDS 0,02% 3.193.839 SH 19 Agu 2026 Harian
VONE · VANGUARD SCOTTSDALE FUNDS 0,02% 16.227 SH 19 Agu 2026 Harian
VTHR · VANGUARD SCOTTSDALE FUNDS 0,02% 8.342 SH 19 Agu 2026 Harian
PRF · Invesco Exchange-Traded Fund Trust 0,02% 11.593 SH 5 Okt. 2026 Harian
TOK · iShares Trust 0,02% 249 SH 11 Sep. 2026 Harian
URTH · iShares, Inc. 0,02% 8.440 SH 11 Sep. 2026 Harian
ACWI · iShares Trust 0,01% 30.548 SH 11 Sep. 2026 Harian
DFLV · Dimensional ETF Trust 0,01% 4.926 NS 31 Juli 2026 N-PORT
DFVX · Dimensional ETF Trust 0,01% 323 NS 31 Juli 2026 N-PORT
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 85.082 SH 19 Agu 2026 Harian
VONV · VANGUARD SCOTTSDALE FUNDS 0,01% 8.319 SH 19 Agu 2026 Harian
FYEE · Fidelity Greenwood Street Trust 0,01% 110 NS 31 Juli 2026 N-PORT
REVS · Columbia ETF Trust I 0,01% 124 NS 31 Juli 2026 N-PORT
IWD · iShares Trust 0,01% 30.627 SH 11 Sep. 2026 Harian
IJH · iShares Trust · 3.528.125 SH 11 Sep. 2026 Harian
IJK · iShares Trust · 582.451 SH 11 Sep. 2026 Harian
XJH · iShares Trust · 13.736 SH 8 Sep. 2026 Harian
ISCB · iShares Trust · 4.526 SH 11 Sep. 2026 Harian

NBIX Konsensus Analis Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan

21
peringkat · 36 analis BELI
Target median $214.00 +47,1%
14 38,9% Beli Kuat
17 47,2% Beli
5 13,9% Tahan
0 0,0% Jual
0 0,0% Jual Kuat

Target Harga 12 Bulan

29 analis · 2026-10-03

Target rata-rata $207.81 +42,8%

← Di bawah semua target Harga saat ini $145.51
Rendah$164.00 Rata-rata$207.81 Tinggi$253.00

Perbandingan rekan (sub-industri GICS) Metrik utama vs rekan sektor

22

Dasar FY, harga per penutupan akhir tahun fiskal terakhir setiap perusahaan.

Ticker Kapitalisasi Pasar P/E Pendapatan YoY Margin Bersih ROE Margin Kotor
NBIX $14.20B 30.4 21.4% 16.7% 16.1% ·
ALNY $52.64B 170.7 65.2% 8.5% 60.4% ·
UTHR $21.27B 17.5 10.6% 41.9% 18.7% 87.9%
INSM $37.29B -27.1 66.7% -210.5% -128.4% ·
INCY $19.60B 15.4 21.2% 25.0% 27.6% ·
EXEL $11.44B 15.7 7.0% 33.7% 37.3% ·
SMMT $13.56B -12.1 · · -235.1% ·
BBIO $14.90B -20.2 126.3% -146.0% 41.2% ·
HALO $7.93B 26.3 37.5% 22.7% 166.1% ·
MDGL $13.30B -45.3 432.1% -30.1% -44.4% ·
TWST $1.71B -21.6 20.3% -20.6% -17.0% ·

Berita Terbaru Berita utama terbaru yang menyebutkan perusahaan ini

23
Opsi Desember 2027 Kini Tersedia untuk Neurocrine Biosciences (NBIX) Nasdaq · 5 bulan, 4 minggu lalu Pasar Saham Hari Ini, 6 April: Soleno Therapeutics Naik Setelah Perjanjian Pembelian Tunai Senilai $2,9 Miliar Nasdaq · 6 bulan lalu Neurocrine Akuisisi Soleno Senilai $2,9 Miliar Tunai; Saham Soleno Meroket di Perdagangan Pra-Pasar Nasdaq · 6 bulan lalu

Sinyal Perdagangan Sinyal beli/jual terbaru dengan harga masuk dan rasio risiko/imbalan

25
BLUECHIP_DIP Stop out Sep 8
risiko 1 imbalan 1,67
masuk $156.04 R:R 1,67
BLUECHIP_DIP Stop out Agu 6
risiko 1 imbalan 2,78
masuk $161.50 R:R 2,78
BLUECHIP_DIP Kedaluwarsa Apr 28
risiko 1 imbalan 5,00
masuk $129.88 R:R 5,00
BLUECHIP_DIP Stop out Apr 20
risiko 1 imbalan 4,80
masuk $132.67 R:R 4,80
BLUECHIP_DIP Stop out Apr 9
risiko 1 imbalan 5,00
masuk $132.79 R:R 5,00

Tidak ada sinyal terbuka saat ini — tidak ada kartu yang terisi, dan itu jujur.

Metrik Saya Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap

26

Pilih metrik yang penting bagi Anda — klik + di sebelah baris mana pun di Fundamental Lengkap di atas.

Pilihan Anda disimpan dan mengikuti Anda di semua ticker.

Sumber: SEC 10-Q diajukan Jul 31, 2026